Nader I. Al-Dewik is a Director of Translational and Precision Medicine Research, Principal Investigator at Hamad Medical Corporation (HMC), and A/Professor in Human Genetics, Genomic and Precision Medicine Program, College of Health and Life Sciences, Hamad Bin Khalifa University (HBKU), Qatar. He was also awarded an innovation fund from Qatar Science and Technology Park (QSTP) to develop a molecular kit. His approach is multidisciplinary and collaborative in nature. He has presented original research findings at several local, regional, and international conferences and published them in peer-reviewed journals. He acts as a reviewer for many cancer and genetics journals. He is also a reviewer of research grant proposals such as The Research Council (TRC) of the Sultanate of Oman and Qatar University Internal Grants. He is a managing editor of "Frontiers in Bioscience" Special Issues, academic editor of "PLOS ONE", and ad hoc reviewer for the journals "BMJ", "PLOS ONE", "Molecular Cancer" (Springer Nature), "BMC" (Springer Nature), "Journal of Translational Medicine", "Epigenetics" (Taylor & Francis), "Journal of Pediatric Genetics", "Meta Gene" (Elsevier), "Journal of Cancer Therapy (JCT)", "Biomarkers in Cancer", "Bioinformatics and Biology Insights", and "Cancer Informatics". ​His major research interests are in addressing high-priority maternal and neonatal health such as inherited genetic disorders, congenital anomalies, cancer/leukemia, and preterm babies.